Press Releases Lonza Group AG Deutsche Boerse AG

Equities

LO3A

US54338V1017

Market Closed - Deutsche Boerse AG Other stock markets 11:35:05 28/06/2024 am IST			5-day change	1st Jan Change
50.5 ^EUR	0.00%		+1.41%	+35.75%

20/06	Berenberg Lifts Price Target on Lonza Group, Maintains Buy Recommendation	MT
14/05	Swiss Market Index Edges Up Ahead of Inflation Report	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lonza : Q1 2024 Qualitative Update	14/05	PU
Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024	14/05	EQ
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved	08/05	EQ
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon	17/04	EQ
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports	03/04	EQ
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer	02/04	EQ
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche	20/03	EQ
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza	26/01	EQ
Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin	26/01	EQ
Lonza : Launches GS Effex® Cell Line for the Development of Therapeutic Antibodies with Increased Potency	14/11	PU
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds	06/11	EQ
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects	17/23/17	EQ
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer	13/23/13	EQ
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023	21/23/21	EQ
Board Announcement	18/23/18	EQ
Lonza : Half-Year 2023 Results Report	21/23/21	PU
Lonza Delivers 5.6% CER Sales Growth, With Underlying Growth at Around 10% CER and 30% CORE EBITDA Margin	21/23/21	EQ
Lonza : Launches TheraPRO® CHO Media System to Improve Productivity and Quality in Therapeutic Protein Manufacture	17/23/17	PU
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes Cell Therapies	27/23/27	AQ
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering	01/23/01	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

LONZA GROUP : Some mixed real-world effects

February 06, 2024 at 09:14 pm IST